IGC-511

**IGC-511** is an investigational **cannabinoid-based small molecule formulation** being developed by **IGC Pharma** for the treatment of pain, particularly **chronic pain, muscular pain, and neuropathic pain**. Publicly available company disclosures describe it as a **new cannabinoid formulation** and patent-stage therapeutic candidate intended for use in **humans and veterinary animals**. The precise molecular composition and specific receptor pharmacology have not been publicly detailed, but secondary drug intelligence sources characterize it broadly as a **cannabinoid receptor modulator**. Development appears to have remained **preclinical** and there is no evidence of marketing approval.